#291 - Why No Diet Wins (and What 40 Years of Nutrition Research Actually Shows) | Christopher Gardner, PhD, & Mike Haney
LEVELS – A Whole New LevelShow Notes
In this episode of A Whole New Level, Christopher Gardner, PhD, joins Mike to discuss his decades in nutrition research, the challenges of conducting randomized controlled trials (RCTs) on diet, and how to communicate complex science to the public. Gardner has led some of the most rigorous research ever comparing dietary approaches in real-world conditions, so his insights about what works (cutting processed food and sugar) and what doesn’t (obsessing about macronutrients) are worth a listen.
Sign Up to Get Your Free Ultimate Guide to Glucose: https://levels.link/wnl
In this episode, we cover: What a nutritional interventionist is – someone who studies people who are asked to change their diet, tracking them and taking samples to see what might have changed. How to square widely-accepted lessons about nutrition (i.e., junk food=bad) with the high degree of individuality in diets that work. The concept of "equipoise" in study design, which means making sure both diets being compared are well-represented versions of that diet (e.g., a "kick butt diet A and a crappy diet B" is avoided). The dilemma of communicating single-study results to the public and the role of the Netflix documentary on Gardner’s famous twin study in making science engaging. Dr. Gardner's experience on the Dietary Guidelines Advisory Committee and the methodology used to reach conclusions. The focus on ultra-processed foods and the need to message the consensus points of eating more whole foods and vegetables, and avoiding added sugar and refined grains. The learnings from the DIETFITS study, which compared low-carb and low-fat diets among 600 people for a year, and why there was more variation among people within a diet than between the two diets.
🎙 What Dr. Christopher Gardner & Mike Haney discuss: [00:33] Nutritional Interventionist Role [02:17] Shortcomings of Nutrition RCTs [03:59] Garlic Study Example [16:48] Concept of Equipoise in Study Design [21:54] Value of Communicating Single Study Results [28:02] Industry Funding and Transparency [33:11] Dietary Guidelines Advisory Committee Methodology [38:48] Ultra-Processed Foods and the Evidence [48:27] Simplicity vs. Complexity in Nutrition [50:24] Consensus on Foundational Diet Components
Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
🔗 Helpful links Watch the conversation: https://youtu.be/ZQ0G_jfwKoM Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
📲 Connect Connect with Christopher Gardner, PhD, on Instagram: https://www.instagram.com/cgardnerphd/?hl=en
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.